Nath Biogene

Business: Engaged in research, processing and producing hybrid seeds including Bt seeds

Biotech Revenue: Rs 11.92 crore

CEO: Nandkishor Kagliwal (MD)

Biotech Revenue: Rs 11.92 crore

Start-up Year: 1981

Address: Nath House, Nath Road, Aurangabad - 431 005

Tel.: 91- 240- 2376314-17

Fax: 91- 240 -2376188

Website: www.nathseeds.com

Nath Biogene, a hybrid seed producing and biotechnology company received GEAC approval for commercial cultivation of NCEH-6 R Bt (for north zone), NCEH-3 R Bt (for south zone)) and NCEH-2R (central zone under rainfed conditions) containing encoding fusion genes (cry 1Ab+Cry 1 Ac) in 2006. Its hybrids were developed using the Chinese technology. It has sold a total of 1.6 lakh packets of Bt cottonseeds during its first year of launch. With this its sales turnover from Bt cottonseeds for the year 2006-07 was Rs 11.92 crore.

In addition to direct sales, it has sub-licensees the technology to other companies. Sub-licensees such as Unipho Seeds and Biogenetics, Zuari Seeds, Navkar Seeds, Sri Rama Agri-Genetics (I) and Daftari Agro have also sold about 1.27 lakh packets of Bt cottonseed packets during 2006-07, of which Unipho Seeds and Biogenetics sold over 1 lakh packets while the rest contribution was meager.

Nath Biogene, independently as well as jointly with its sister organization Global Trangenes (India), has forged R&D linkages with several renowned institutions in the world with an objective of collection, evaluation and utilization of germplasm for all the target crops, to develop elite genetic stocks, breeding lines and products conferring enhanced resistance/ tolerance to biotic and abiotic stresses and for development of F1 hybrids in cotton, paddy, maize, bajra, jowar, sunflower, mustard and pigeon pea. It has highly specialized ELISA testing facility, where thousands of qualitative and quantitative Bt protein estimations of its own test materials from field trials and Bt cottonseeds. The services of this facility are also extended to its the sub-licensees of the GTL's fusion-gene Bt technology.